Biotech Content Marketing: Why Most Companies Get the Audience Wrong

Biotech content marketing is the practice of creating and distributing scientific, commercial, and educational content to move target audiences, whether investors, clinicians, regulators, or patients, through a defined decision-making process. Done well, it builds credibility in a sector where credibility is the only currency that matters. Done badly, it produces polished noise that no one with real influence ever reads.

Most biotech companies produce content. Very few have a content strategy. The difference is significant, and it tends to show up at exactly the wrong moment: a funding round, a partnership negotiation, a product launch.

Why Biotech Is a Different Content Environment

I’ve worked across more than 30 industries in my career, from fast-moving consumer goods to financial services to public sector. Biotech sits in a category of its own, not because the fundamentals of content marketing change, but because the stakes attached to every piece of content are unusually high.

A poorly worded clinical claim can attract regulatory scrutiny. An investor update that overstates pipeline progress can create legal exposure. A patient-facing piece that oversimplifies mechanism of action can erode the trust of the clinicians who refer to you. The margin for carelessness is thin.

That context shapes everything: how content gets approved, who contributes to it, how quickly it can be produced, and what “good” looks like. It also explains why so much biotech content ends up bland. The review process strips out anything that could be construed as a claim, and what remains is technically accurate but commercially useless.

The companies that get this right treat content strategy as a discipline that runs alongside regulatory and legal, not beneath it. The goal is content that is both defensible and effective. Those two things are not mutually exclusive, but achieving both requires deliberate design from the start.

If you’re building content strategy across the broader life sciences space, the Content Strategy & Editorial hub covers the frameworks and principles that apply across regulated and complex B2B environments.

Who Are You Actually Writing For?

This is where most biotech content programmes go wrong before they’ve written a single word. The audience in biotech is not one person. It is rarely even one type of person. And the mistake I see repeatedly is companies defaulting to the audience they find most comfortable, usually other scientists, and ignoring everyone else who has a hand in their commercial future.

Consider a mid-stage biotech with a novel oncology asset. The content audiences include: venture and institutional investors evaluating pipeline risk and return; oncologists and KOLs assessing clinical plausibility and differentiation; regulatory affairs professionals at potential partners; patient advocacy groups who influence trial recruitment; and business development teams at larger pharma companies who need to understand the commercial thesis quickly.

Each of those audiences reads differently, trusts different signals, and makes decisions on different timelines. A white paper written for a haematologist will not land with a VP of Business Development at a large pharma. A press release written for investors will confuse a patient advocate. Yet I regularly see biotech companies producing one type of content and expecting it to serve all of these audiences simultaneously.

The fix is not to produce more content. It is to map each audience explicitly, define what decision you are trying to influence for each, and then build content that speaks directly to that decision. That sounds obvious. It rarely gets done.

For a parallel example of how audience segmentation works in a similarly complex regulated environment, the approach to Ob Gyn content marketing illustrates how clinical, patient, and commercial audiences require distinct content treatments even within a single therapeutic area.

The Credibility Problem That Content Has to Solve

In most industries, content marketing builds awareness and preference. In biotech, it primarily builds credibility. That is a different job, and it requires a different approach to what you publish, where you publish it, and who is attached to it.

Credibility in biotech comes from a small number of sources: peer-reviewed publication, endorsement by recognised KOLs, citation by analysts with standing in your sector, and a track record of doing what you said you would do. Content marketing can support all of these, but it cannot replace any of them.

What content can do is make the credibility signals you already have more visible and more accessible. A clinical trial result buried in a journal abstract reaches a limited audience. A well-structured content programme, built around that result, can place it in front of the investors, partners, and clinicians who need to see it, in a format they will actually read.

This is where analyst relations becomes relevant. The major industry analysts, whether covering diagnostics, therapeutics, or medtech, are credibility amplifiers. Getting your science and your commercial thesis in front of the right analysts, and having them reference your work in their reports, is worth more than most content assets a biotech company could produce. Understanding how an analyst relations agency operates, and how it intersects with content strategy, is worth the time for any biotech marketing team thinking seriously about credibility at scale.

The Content Marketing Institute’s framework on story-driven content is a useful reference point here. The instinct in biotech is to lead with data. That is not wrong, but data without narrative context rarely moves anyone. The companies that communicate their science most effectively tend to build a clear story around their data, one that explains not just what they found but why it matters and for whom.

What Content Types Actually Work in Biotech

Early in my career, I had a habit of reaching for the most visible content format rather than the most appropriate one. I learned to stop doing that. In biotech, the format question matters more than in most sectors because your audiences have strong priors about what constitutes a credible source.

For scientific and clinical audiences, long-form content still dominates. White papers, technical briefings, and peer-reviewed publications carry weight that a blog post never will. That does not mean blog content has no place, but it means you need to be clear about what job each format is doing. A blog post can create awareness and drive traffic. It cannot establish scientific credibility on its own.

For investor audiences, the content that works tends to be precise, forward-looking, and grounded in evidence. Pipeline updates, mechanism of action explainers, and competitive landscape analyses all perform well when they are written with enough specificity to be useful rather than enough vagueness to be safe. Investors read a lot of biotech content. They recognise evasion quickly.

For patient and advocacy audiences, the register shifts entirely. Empathetic content that centres the patient experience, written in plain language without condescension, builds the kind of trust that influences trial recruitment and brand perception in ways that scientific content cannot. This is an area where many biotech companies underinvest, partly because it sits outside the scientific culture of the organisation.

Video is underused in biotech relative to its potential. A well-produced explainer on mechanism of action, or a recorded conversation between two credible KOLs, can reach audiences that would never read a white paper. Copyblogger’s case for video content is worth reading if your team is still treating video as an afterthought.

The broader life sciences content landscape, including how content strategy differs across therapeutics, diagnostics, and devices, is covered in more depth in the piece on life science content marketing.

Distribution Is Where Biotech Content Programmes Collapse

I spent several years running performance marketing at scale, managing significant ad spend across dozens of clients. One thing that experience teaches you is that distribution is not a secondary concern. It is at least as important as the content itself, often more so.

Biotech companies tend to produce content and then publish it on their own website, send it to their existing email list, and post it on LinkedIn. That is not a distribution strategy. It is content recycling. It reaches the people who already know you, which has some value, but it does almost nothing to extend your reach to the audiences who have not yet encountered your work.

Effective distribution in biotech requires deliberate channel selection for each audience type. For clinical audiences, that might mean working with medical education platforms, contributing to specialist publications, or building relationships with conference organisers who can amplify your content to their audiences. For investor audiences, it might mean ensuring your content is indexed and discoverable by the analyst platforms your target investors use.

Paid distribution has a role here too, though it requires care in a regulated environment. Sponsored content in specialist publications, targeted LinkedIn campaigns reaching specific job titles and company types, and programmatic placements against relevant content categories can all extend reach efficiently when the targeting is tight enough to be meaningful.

The goal-setting and measurement framework from Moz on content marketing goals and KPIs is a useful starting point for biotech teams that have been producing content without clear metrics. The metrics that matter in biotech tend to differ from those in consumer or SaaS marketing: you are often optimising for quality of engagement over volume of traffic, and for reach within a defined professional audience rather than broad awareness.

The Content Audit: Start Here If You Have an Archive

Most biotech companies that come to us with a content problem have the same underlying issue: they have accumulated a body of content over several years, produced by different people, for different purposes, with no consistent strategic thread. The content exists. Whether it is doing anything useful is a different question.

A content audit is the right starting point in this situation. Not because auditing is more interesting than creating, but because building on top of a weak or contradictory content foundation compounds the problem. You end up with more content that does not hang together, more mixed signals to your audiences, and more resource spent maintaining assets that should have been retired or consolidated.

The audit process for biotech content should assess each piece against a small number of questions: Which audience is this for? What decision is it designed to influence? Is the science current and accurate? Is the commercial framing still relevant? Is it indexed and discoverable? The answers will tell you quickly what to keep, what to update, and what to remove.

The methodology for a rigorous content audit is well documented in the context of SaaS companies, and many of the same principles apply in biotech. The content audit for SaaS framework is worth reviewing for the structural approach, even if the specific content categories differ.

One practical note: in biotech, the audit should involve medical or scientific review alongside the marketing assessment. Content that was accurate three years ago may not reflect current data, regulatory guidance, or competitive positioning. Publishing outdated scientific content is a credibility risk that most marketing teams do not have the domain expertise to catch on their own.

Building a Content Programme That Scales With Your Pipeline

One of the structural challenges in biotech content marketing is that the business itself changes shape rapidly. A company at pre-IND stage has different content needs than one at Phase 2, and different again at commercialisation. The content programme needs to be designed to scale and shift with the pipeline, not built as a fixed infrastructure that becomes obsolete when the business moves.

Early-stage companies should focus their content energy on a small number of high-quality assets that establish scientific credibility and communicate the commercial thesis clearly. A detailed mechanism of action explainer, a competitive landscape analysis, and a clear articulation of unmet need will serve more purposes across more audiences than a high-volume blog programme ever will.

As the pipeline matures and clinical data accumulates, the content programme should build around that data. Trial results, interim analyses, and regulatory milestones are all content events that deserve structured communication plans, not just press releases. The companies that do this well treat each data readout as a content campaign, not a single announcement.

At the commercial stage, the content needs shift toward supporting adoption: clinical education, formulary decision support, patient identification tools, and health economics content that helps payers understand value. This is a different discipline from the pre-commercial content work, and it requires different contributors, different distribution channels, and different success metrics.

For companies operating across multiple therapeutic areas or multiple geographies, the complexity multiplies. The principles that apply to content marketing for life sciences at scale are worth understanding before you try to build a programme that spans multiple assets and markets simultaneously.

It is also worth noting that some of the most useful lessons in content programme design come from sectors that seem unrelated to biotech. The discipline required to build content that serves complex procurement processes in government contracting, for instance, has more in common with biotech content than most people would expect. The B2G content marketing framework illustrates how to build content that influences multi-stakeholder decisions over long sales cycles, which maps closely to the biotech commercial environment.

The Measurement Question

When I was at iProspect, growing the business from a small team to one of the top-five agencies in the market, one of the persistent tensions was between clients who wanted precise attribution and the reality that most content influence is not directly attributable. That tension is even more pronounced in biotech, where the sales cycle can span years and the decision-making unit is large and distributed.

The answer is not to abandon measurement. It is to measure the right things and resist the pressure to reduce everything to last-click attribution or short-term conversion metrics. In biotech content marketing, the meaningful indicators tend to be: reach within your defined professional audience, quality of engagement (time on page, scroll depth, return visits), content-influenced pipeline (tracked through CRM integration), and qualitative signals like citation by analysts, mention in industry publications, or reference by KOLs in their own communications.

The Moz perspective on content marketing in the current AI environment is relevant here too. The question of what content achieves in a world where AI is changing how people find and consume information is one that biotech teams need to be thinking about now, not in two years. The credibility signals that matter most in biotech, peer review, analyst endorsement, KOL citation, are precisely the signals that AI-generated content cannot replicate. That is a structural advantage for companies that invest in genuine expertise-driven content.

If you are building or rebuilding a content programme from the ground up, the broader frameworks in the Content Strategy & Editorial section cover the planning, governance, and measurement principles that apply across complex B2B environments including biotech.

What Good Biotech Content Actually Looks Like

I judged the Effie Awards for a period, which gave me a useful lens on what separates marketing that actually works from marketing that looks good in a case study. The pattern in effective campaigns, across every sector, is the same: clarity of audience, clarity of objective, and content that is genuinely useful to the person reading it rather than primarily flattering to the organisation that produced it.

In biotech, good content is specific. It does not gesture at science, it explains it. It does not describe unmet need in vague terms, it quantifies it where possible and contextualises it where not. It does not overclaim, because the audience is too sophisticated for overclaiming to work, and the regulatory environment makes it risky anyway.

Good biotech content is also honest about uncertainty. One of the things that erodes credibility fastest in this sector is content that presents everything as settled when the audience knows it is not. Acknowledging what is unknown, what is still in development, what the data does and does not show, is not a weakness. It is a signal that the organisation producing the content can be trusted.

Early in my career, when I built my first company website from scratch because the budget was not there to commission one, I learned something that has stayed with me: the constraint of having to do something yourself forces a clarity that commissioning it from someone else often does not. When you have to write every word yourself, you cannot hide behind production values. The content has to work on its own terms. That discipline, writing content that works without the benefit of design or production to prop it up, is a useful test for any biotech content team. If the argument does not hold up in plain text, it will not hold up in a polished white paper either.

About the Author

Keith Lacy is a marketing strategist and former agency CEO with 20+ years of experience across agency leadership, performance marketing, and commercial strategy. He writes The Marketing Juice to cut through the noise and share what works.

Frequently Asked Questions